The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01E | Protein kinase inhibitors | |
| 4 | L01ED | Anaplastic lymphoma kinase (ALK) inhibitors | |
| 5 | L01ED05 |
| Active Ingredient | Description | |
|---|---|---|
| Lorlatinib |
Lorlatinib is a selective, adenosine triphosphate (ATP)-competitive inhibitor of ALK and c-ros oncogene 1 (ROS1) tyrosine kinases. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| LORBRENA Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| LORVIQUA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
